Chitosan Dressings to Facilitate Safe Effective Debridement of Chronic Wounds & Minimize Wound Bacterial Re-colonization

NCT01035944 | Terminated Results

• 1 other identifier: HC-NU-2009-01
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine if the use of HemCon chitosan-based dressings is effective to facilitate safe, effective debridement of chronic wounds in the operating room and inpatient ward settings and to minimize bacterial re-colonization of wounds.

Conditions

Wound Debridement

Keywords

Chronic wounds; Chronic wound debridement; Debridement; Bedside debridement; Surgical debridement; Wound debridement; Minimize bacterial re-colonization of wounds; HemCon ChitoGauze Dressings; HemCon Dressings; Chitosan-based dressings

Outcome Measures

Primary Outcomes (1)

• Demonstrate That Debridements Using HemCon Dressings at Bedside Can be Performed Safely Without Excessive Bleeding; Compare Levels of Bacterial Load Between Debrided Wounds Treated With HemCon Dressings vs. Wounds Treated With Gauze & Saline Dressings.

  2 days and 5 days after debridement.

Secondary Outcomes (1)

• Determine Cost Efficacy, Hemostasis and Patient Comfort Between Wounds Debrided at Bedside With HemCon Dressings & Wounds Debrided in Operating Room Setting.

  2 days and 5 days after debridement.

Study Arms (4)

HemCon Operating Room

EXPERIMENTAL

The HemCon dressing is the intervention for the HemCon Operating Room arm. The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.

Device: HemCon Dressings and HemCon ChitoGauze; chitosan-based.

Control Operating Room

ACTIVE COMPARATOR

The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.

Device: Gauze and saline dressings.

HemCon Bedside

EXPERIMENTAL

The intervention for the HemCon Beside arm is the HemCon Dressing. The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.

Device: HemCon Dressings and HemCon ChitoGauze; chitosan-based.

Control Bedside.

ACTIVE COMPARATOR

The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.

Device: Gauze and saline dressings.

Interventions

HemCon Dressings and HemCon ChitoGauze; chitosan-based. DEVICE

Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.

Also known as: HemCon Dressings, HemCon ChitoGauze.

HemCon Bedside; HemCon Operating Room

Gauze and saline dressings. DEVICE

Control for both settings will be gauze and saline dressings.

Control Bedside.; Control Operating Room

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \> 18 years and are able to provide written informed consent.
• Have a wound on their body with an eschar and/or significant slough present
• Documented laboratory studies and coagulation profiles prior to the debridement (including hematocrit, hemoglobin, white blood count, total lymphocyte count, albumin, pre-albumin, HbA1C in patients with diabetes)
• Subjects with a hemoglobin \< 9 g/dL must have one unit of blood typed and cross matched prior to the debridement; all other subjects must have an active type and screen performed prior to the debridement procedure.
• Subjects must be willing to consent to a blood transfusion in the rare event that a transfusion is necessary.
• Must be expected to be inpatients for at least 5 days following debridement, to enable controlled dressing changes by the service.
• Female subjects of childbearing age must not be pregnant, and must consent to utilize an appropriate method of contraception during the course of the study.
• For subjects that are to undergo a debridement in the operating room:
• Subjects must be sensate or have wounds that are sufficiently large to warrant a debridement in the OR
• Wounds must require more than a simple eschar removal, or must be extensive enough that an operating room debridement would be more appropriate.
• Subjects must be candidates for regional or general anesthesia, unless the wound occurs in an insensate body part (for example, a pressure sore in a paraplegic or quadriplegic patient, or a diabetic foot ulcer in a patient with a dense diabetic polyneuropathy).
• For subjects that are to undergo a debridement in the bedside setting:
• The part of the wound that is to be debrided must be mostly an eschar and necrotic tissue which is not likely to have significant bleeding.
• Subjects must be insensate, or the wound must be less than 50 cm2 such that the use of local anesthesia in the wound can be undertaken.

You may not qualify if:

• Pre-debridement hemoglobin level \< 7.0 g/dL
• Not candidates for or refuse blood transfusions
• Unable to provide written informed consent
• Subjects with sensitivity to chitosan or the gauze dressings used in this study, or any local anesthetic needed for a debridement
• Subjects who are in the intensive care unit
• Subjects who, in the opinion of the Investigator, may not complete the study for any reason.
• Have grossly infected wounds that may reasonably be expected to require multiple debridement procedures prior to clearance of bacteria and nonviable tissue from the wound.
• For wounds situated in the lower extremity, leg must have either palpable pulses or else an ABI \> 0.4

Sponsors & Collaborators

• HemCon Medical Technologies, Inc: lead

Study Sites (1)

Northwestern University

Chicago, Illinois, 60611, United States

Location

Limitations and Caveats

Early termination of the study; unable to reach enrollment milestones. No outcome measure data was analyzed; zero participants were analyzed.

Results Point of Contact

• Title: Dr. Jody Oyama
• Organization: HemCon Medical Technolgoies

jody.oyama@hemcon.com

503.245.0459

Study Officials

• Robert D. Galiano, M.D.

  Northwestern Memorial Hospital, Division of Plastic Surgery

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 17, 2009
• First Posted: December 21, 2009
• Study Start: February 1, 2010
• Primary Completion: March 1, 2012
• Study Completion: March 1, 2012
• Last Updated: July 1, 2014
• Results First Posted: June 9, 2014

Record last verified: 2014-05

Locations

US (1)